DCF Advisers LLC Boosts Holdings in Zai Lab Limited (NASDAQ:ZLAB) (2025)

DCF Advisers LLC grew its position in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 53.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 64,750 shares of the company's stock after buying an additional 22,500 shares during the quarter. DCF Advisers LLC owned 0.06% of Zai Lab worth $1,696,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ZLAB. US Bancorp DE raised its holdings in Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after purchasing an additional 5,534 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Zai Lab during the 3rd quarter worth approximately $225,000. Daiwa Securities Group Inc. lifted its holdings in shares of Zai Lab by 4,851.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company's stock valued at $231,000 after buying an additional 9,364 shares during the period. RBF Capital LLC purchased a new stake in shares of Zai Lab in the third quarter valued at approximately $241,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Zai Lab by 15.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock worth $290,000 after acquiring an additional 1,502 shares during the period. Institutional investors and hedge funds own 41.65% of the company's stock.

Insider Buying and Selling at Zai Lab

In related news, insider Rafael Amado sold 7,583 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now owns 33,834 shares of the company's stock, valued at $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ying Du sold 50,000 shares of the business's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the transaction, the chief executive officer now directly owns 494,117 shares of the company's stock, valued at $17,032,212.99. The trade was a 9.19 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 125,127 shares of company stock worth $4,139,672. 13.88% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Bank of America reissued a "neutral" rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. Scotiabank initiated coverage on shares of Zai Lab in a report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th. Finally, Cantor Fitzgerald raised Zai Lab to a "strong-buy" rating in a research note on Tuesday, March 4th.

View Our Latest Report on ZLAB

Zai Lab Stock Up 1.7 %

Shares of Zai Lab stock traded up $0.58 on Monday, hitting $35.67. The company's stock had a trading volume of 879,274 shares, compared to its average volume of 752,048. The company has a market capitalization of $3.91 billion, a P/E ratio of -12.88 and a beta of 1.08. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $39.61. The firm has a fifty day moving average price of $30.91 and a 200-day moving average price of $27.92.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. As a group, analysts expect that Zai Lab Limited will post -2.58 earnings per share for the current year.

Zai Lab Company Profile

(Free Report)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

Further Reading

• Five stocks we like better than Zai Lab
• CD Calculator: Certificate of Deposit Calculator
• Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
• Stock Splits, Do They Really Impact Investors?
• Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
• Want to Profit on the Downtrend? Downtrends, Explained.
• D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?

Should You Invest $1,000 in Zai Lab Right Now?

Before you consider Zai Lab, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.

While Zai Lab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here